{
    "body": "Which enzyme is inhibited by ribociclib?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26303211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27729458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27017286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25941111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26642065", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27030077", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27496135", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26830312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27717303", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25848011", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26053278", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27810861", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27542767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27087139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26995305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27336726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26390342", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25876993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26896604"
    ], 
    "ideal_answer": [
        "Ribociclib is inhibitor of cyclin D-cyclin-dependent kinase 4/6 (CDK 4/6). It is used for breast cancer treatment."
    ], 
    "exact_answer": [
        "cyclin D-cyclin-dependent kinase 4/6", 
        "CDK4/6"
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798"
    ], 
    "type": "factoid", 
    "id": "5880dba9c872c95565000009", 
    "snippets": [
        {
            "offsetInBeginSection": 411, 
            "offsetInEndSection": 587, 
            "text": "Three CDK 4/6 inhibitors have been investigated for the treatment of HR(+) breast cancer, including palbociclib (PD 0332991), ribociclib (LEE011), and abemaciclib (LY2835219). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26303211", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 472, 
            "offsetInEndSection": 761, 
            "text": "The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1054, 
            "offsetInEndSection": 1405, 
            "text": "SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1339, 
            "offsetInEndSection": 1512, 
            "text": "Currently, three selective CDK4/6 inhibitors have been approved or are in late-stage development: palbociclib (PD-0332991), ribociclib (LEE011), and abemaciclib (LY2835219).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27017286", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 276, 
            "text": "The combination of antiestrogen therapy and ribociclib, an investigational CDK4/6 inhibitor, led to improved outcomes in women with metastatic HR-positive, HER2-negative breast cancer, according to findings presented at a meeting of the European Society for Medical Oncology. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810861", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 353, 
            "text": "OBJECTIVES: Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). This study assessed the biological activity of ribociclib (LEE011; CDK4/6 inhibitor) plus letrozole compared with single-agent letrozole in the presurgical setting", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336726", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 406, 
            "offsetInEndSection": 559, 
            "text": "Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 547, 
            "offsetInEndSection": 803, 
            "text": "After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell cycle analysis, Ki67 immunostaining, timelapse microscopy and xenograft studies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729458", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 274, 
            "offsetInEndSection": 635, 
            "text": "Methods In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717303", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 522, 
            "offsetInEndSection": 795, 
            "text": "Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941111", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 90, 
            "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 874, 
            "offsetInEndSection": 1102, 
            "text": "Targeted inhibition of CDK4/6 pathway by small-molecule inhibitors palbociclib (PD-0332991) and ribociclib (LEE011) resulted in inhibition of cell-cycle progression, amelioration of kidney injury, and improved overall survival. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848011", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 91, 
            "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", 
            "endSection": "title"
        }
    ]
}